|
Mar 27
|
IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024
|
|
Jan 16
|
IceCure Medical's ProSense® Featured at Indian Society of Vascular and Interventional Radiology Conference: Key Opinion Leaders Highlight Benefits of Cryoablation
|
|
Jan 12
|
IceCure Medical Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
|
|
Jan 10
|
IceCure Medical CEO Issues Letter to Shareholders & Reports Increase in Sales in Preliminary Unaudited 2023 Results
|
|
Nov 29
|
IceCure's ProSense® Deepens Regulatory Approval in India
|
|
Nov 28
|
IceCure System Successfully Treated Kidney Cancer Tumor with 92% Disease-Free Survival Rate and 100% Secondary Local Control Rate
|
|
Nov 8
|
IceCure Medical to Report Third Quarter 2023 Financial & Operational Results on November 15, 2023
|
|
Nov 6
|
Substantial Evidence-Based Data Currently Being Generated by 19 Ongoing Studies Using IceCure Medical's ProSense® Cryoablation System
|
|
Nov 5
|
Here's Why We're Watching IceCure Medical's (NASDAQ:ICCM) Cash Burn Situation
|
|
Nov 3
|
IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification
|
|
Aug 7
|
IceCure Medical to Report Second Quarter 2023 Financial & Operational Results on August 14, 2023
|
|
Apr 24
|
IceCure Medical to Provide Educational Support in a First-of-its-Kind Cryotherapy Course at the American Society of Breast Surgeons' 24th Annual Meeting
|